GO:0030366 molybdopterin synthase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030366 (molybdopterin synthase activity) catalyzes the final step of molybdopterin biosynthesis: conversion of precursor Z to molybdopterin.
• The enzyme is a heterotetramer (MoaE/MoaD in bacteria; CnxG/CnxH in eukaryotes) and requires a sulfurtransferase system for activation.
• Molybdopterin is an essential cofactor for molybdenum-dependent enzymes (e.g., sulfite oxidase, xanthine dehydrogenase, aldehyde oxidase).
• Loss-of-function mutations in molybdopterin synthase genes cause molybdenum cofactor deficiency, a severe neonatal neurological disorder.
• Structural and mutational studies have clarified the catalytic mechanism, including the role of a conserved cysteine and the dithiolene formation.
• CRISPR-based models (KO, point mutation, knock-in, overexpression) are powerful tools to dissect molybdopterin synthase function and disease mechanisms.
Description
Molybdopterin synthase activity (GO:0030366) is a molecular function that catalyzes the conversion of precursor Z to molybdopterin, the final step in molybdopterin biosynthesis. Molybdopterin is a unique pterin-based cofactor that coordinates molybdenum in the active sites of molybdenum-dependent enzymes, which are involved in diverse metabolic processes such as purine catabolism, sulfite detoxification, and nitrate assimilation. The enzyme is conserved across all kingdoms of life, from bacteria to humans, and its dysfunction leads to molybdenum cofactor deficiency, a devastating metabolic disorder. Understanding the molecular mechanism, structure, and regulation of molybdopterin synthase is therefore critical for both basic biochemistry and clinical research.
molybdopterin synthase activity At A Glance
| GO ID | GO:0030366 |
|---|---|
| GO term | molybdopterin synthase activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Catalysis of the conversion of precursor Z to molybdopterin, the final step in molybdopterin biosynthesis |
| EC number | Not assigned in QuickGO |
| Reaction | precursor Z + thiocarboxylated MoaD -> molybdopterin + MoaD |
| Subunits | MoaE (small subunit) and MoaD (large subunit) in bacteria; CnxG and CnxH in eukaryotes |
| Cofactor requirement | MoaD requires activation by MoeB/MoaB-mediated thiocarboxylation |
| Pathway | Molybdenum cofactor biosynthesis |
| Disease association | Molybdenum cofactor deficiency |
What Is GO:0030366?
According to the Gene Ontology, molybdopterin synthase activity (GO:0030366) is defined as the catalysis of the conversion of precursor Z to molybdopterin, the final step in molybdopterin biosynthesis. This activity is carried out by a heterotetrameric enzyme complex that uses a sulfurtransferase system to insert sulfur into precursor Z, forming the dithiolene moiety of molybdopterin.
Why Is molybdopterin synthase activity Important in Cell Biology?
Molybdopterin synthase activity is essential for the biosynthesis of the molybdenum cofactor (Moco), which is required for the activity of all molybdenum-dependent enzymes. These enzymes participate in key metabolic pathways, including the catabolism of purines, the detoxification of sulfite, and the assimilation of nitrate in plants and bacteria. In humans, mutations in the genes encoding molybdopterin synthase subunits lead to molybdenum cofactor deficiency, a rare but severe autosomal recessive disorder characterized by neonatal seizures, developmental delay, and early death. Thus, understanding this enzyme is crucial for diagnosing and potentially treating Moco-related diseases, as well as for biotechnological applications.
• Molybdopterin synthase catalyzes the final step of molybdopterin biosynthesis, a key cofactor for molybdenum enzymes.
• Molybdenum cofactor deficiency is a severe neurological disorder caused by defects in molybdopterin synthase genes.
• The enzyme is conserved from bacteria to humans, making it a model for studying enzyme evolution and mechanism.
• Structural studies have revealed a unique mechanism involving a thiocarboxylated MoaD and a conserved cysteine.
• Molybdopterin synthase is a potential target for antimicrobial drug development in pathogens like Mycobacterium tuberculosis.
• The enzyme's activity can be regulated by the availability of its substrates and the sulfurtransferase system.
• Defects in molybdopterin synthase lead to accumulation of precursor Z, which can be used as a diagnostic marker.
• CRISPR-based gene editing enables precise modeling of molybdopterin synthase mutations for drug discovery.
• Understanding molybdopterin synthase can inform strategies for enzyme replacement or cofactor therapy.
• The enzyme's mechanism provides insights into sulfur transfer reactions in biology.
What Happens During molybdopterin synthase activity?
Substrate Binding and Activation
In simple terms: The enzyme first grabs its starting material and gets its sulfur donor ready.
Molybdopterin synthase is a heterotetramer composed of two small subunits (MoaE) and two large subunits (MoaD) in bacteria, or CnxG and CnxH in eukaryotes. The large subunit MoaD must be activated by a sulfurtransferase (MoeB or MoaB) to form a thiocarboxylate at its C-terminus, which serves as the sulfur donor. The substrate, precursor Z, binds to the enzyme, positioning the dithiolene-forming site near the thiocarboxylate.
Catalytic Conversion of Precursor Z to Molybdopterin
In simple terms: The enzyme transfers sulfur to the precursor, turning it into the mature cofactor.
The catalytic mechanism involves the transfer of sulfur from the thiocarboxylated MoaD to precursor Z, resulting in the formation of the dithiolene moiety of molybdopterin. A conserved cysteine residue in the small subunit (MoaE) is essential for catalysis, acting as a nucleophile or in sulfur transfer. Mutational studies have confirmed that substitution of this cysteine abolishes activity. The reaction also requires the hydrolysis of ATP by the sulfurtransferase to activate MoaD.
Product Release and Enzyme Turnover
In simple terms: After making molybdopterin, the enzyme releases it and resets for another round.
Following the formation of molybdopterin, the product is released, and the enzyme undergoes conformational changes to reset for the next catalytic cycle. The thiocarboxylated MoaD is regenerated by the sulfurtransferase system, which recycles the sulfur donor. Thermodynamic studies have shown that subunit interactions are critical for stability and activity, with the heterotetramer being the active form.
Key Genes Involved in GO:0030366 molybdopterin synthase activity
The following genes and proteins are directly involved in molybdopterin synthase activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MOCS2 | Encodes both subunits of human molybdopterin synthase (MOCS2A and MOCS2B) | Mutations cause molybdenum cofactor deficiency; target for gene therapy |
| MOCS3 | Human sulfurtransferase that activates MOCS2A | Required for molybdopterin synthase activity; mutations cause Moco deficiency |
| MOCS1 | Involved in the first step of molybdopterin biosynthesis (precursor Z synthesis) | Mutations cause Moco deficiency type A; not directly molybdopterin synthase but related |
| GPHN | Gephyrin, a multifunctional protein that in humans may have a role in Moco biosynthesis | Potential interaction with molybdopterin synthase; not fully characterized |
| MoaE | Small subunit of bacterial molybdopterin synthase | Model for studying catalytic mechanism; conserved cysteine |
| MoaD | Large subunit of bacterial molybdopterin synthase; carries sulfur | Thiocarboxylate formation is essential; target for mutational studies |
| MoeB | Sulfurtransferase that activates MoaD | Required for MoaD thiocarboxylation; studied for mechanism |
| MoaX | Fused molybdopterin synthase in Mycobacterium tuberculosis | Cleavage is necessary for activity; potential drug target |
| CnxG | Eukaryotic small subunit of molybdopterin synthase (Aspergillus nidulans) | Model for eukaryotic enzyme; mutations affect activity |
| CnxH | Eukaryotic large subunit of molybdopterin synthase (Aspergillus nidulans) | Model for eukaryotic enzyme; mutations affect activity |
| MOCS2A | Small subunit of human molybdopterin synthase | Contains conserved cysteine; mutations cause disease |
| MOCS2B | Large subunit of human molybdopterin synthase | Thiocarboxylated by MOCS3; mutations cause disease |
| NFS1 | Cysteine desulfurase involved in sulfur transfer for Moco biosynthesis | Provides sulfur for MOCS3; not directly molybdopterin synthase |
| SUOX | Sulfite oxidase, a molybdenum enzyme requiring Moco | Deficiency leads to sulfite toxicity; model for Moco disorders |
| XDH | Xanthine dehydrogenase, a molybdenum enzyme | Requires Moco; involved in purine metabolism |
| AOX1 | Aldehyde oxidase, a molybdenum enzyme | Requires Moco; drug metabolism |
| MOCOS | Molybdenum cofactor sulfurase | Adds sulfur to Moco; not molybdopterin synthase but related |
| MoaA | Involved in precursor Z synthesis in bacteria | Not molybdopterin synthase but part of pathway |
How Is molybdopterin synthase activity Regulated?
Molybdopterin synthase activity is regulated at multiple levels. The availability of precursor Z and the thiocarboxylated MoaD/MOCS2A are rate-limiting. The sulfurtransferase MoeB/MOCS3, which activates MoaD, is itself regulated by the cellular sulfur status and ATP levels. In Escherichia coli, the moa operon is regulated by molybdenum availability via the ModE repressor, but direct regulation of molybdopterin synthase has not been extensively studied. In eukaryotes, the expression of MOCS2 is likely regulated by transcription factors responsive to oxidative stress and metal availability, but specific mechanisms remain to be elucidated. Thermodynamic studies indicate that subunit interactions are critical for stability and activity, suggesting that assembly is a regulatory point.
molybdopterin synthase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MOCS2 | Molybdenum cofactor deficiency type B | Patient-derived fibroblasts; MOCS2 knockout mice |
| MOCS3 | Molybdenum cofactor deficiency | MOCS3 knockout cell lines; zebrafish models |
| MOCS1 | Molybdenum cofactor deficiency type A | MOCS1 knockout mice; iPSC-derived neurons |
| SUOX | Isolated sulfite oxidase deficiency | SUOX knockout mice; patient fibroblasts |
| GPHN | Hyperekplexia and Moco deficiency-like | GPHN knockout mice; neuronal cultures |
Molybdenum Cofactor Deficiency
Molybdenum cofactor deficiency (MoCD) is a rare autosomal recessive disorder caused by mutations in genes involved in Moco biosynthesis, including MOCS2 (encoding molybdopterin synthase subunits) and MOCS3. Patients typically present with neonatal seizures, feeding difficulties, developmental delay, and brain atrophy, often leading to early death. The accumulation of sulfite and S-sulfocysteine due to deficient sulfite oxidase activity is a hallmark. Diagnosis is confirmed by elevated urinary sulfite, xanthine, and hypoxanthine, and by genetic testing. Treatment options are limited, but dietary restriction of sulfur-containing amino acids and supplementation with molybdenum or precursor Z (in some cases) have been attempted.
Neurological Manifestations
The neurological symptoms of MoCD are severe and include intractable seizures, hypotonia, and cerebral atrophy. These are primarily due to the toxicity of sulfite and the lack of sulfate, which is essential for brain development. Molybdopterin synthase deficiency specifically leads to the accumulation of precursor Z, which can be detected in urine and used as a biomarker. The severity of the disease depends on the residual activity of the enzyme, with some mutations allowing partial function.
Potential Therapeutic Approaches
Current management of MoCD is supportive, but several therapeutic strategies are under investigation. These include dietary supplementation with molybdenum, which can restore activity of some mutant enzymes, and cell-penetrating precursor Z for MoCD type A. Gene therapy approaches using viral vectors to deliver functional MOCS2 are being explored in preclinical models. CRISPR-based gene editing offers a potential cure by correcting mutations in patient-derived cells.
From molybdopterin synthase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of MOCS2 loss on molybdopterin synthase activity? | MOCS2 knockout cell lines (e.g., HEK293T) generated by CRISPR |
| How do specific point mutations in MOCS2 affect enzyme function? | Point-mutation knock-in cell lines (e.g., MOCS2 Cys->Ser) |
| Can we restore Moco biosynthesis by expressing wild-type MOCS2? | Knock-in of wild-type MOCS2 into mutant cells |
| What is the subcellular localization of molybdopterin synthase? | Tagged knock-in of MOCS2 with GFP or FLAG |
| Can overexpression of MOCS2 rescue MoCD phenotypes? | Overexpression of MOCS2 in patient fibroblasts |
| What is the role of MoaX cleavage in Mycobacterium tuberculosis? | MoaX knockout and point mutants in M. tuberculosis |
How to Study the molybdopterin synthase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC | Molybdopterin and precursor Z levels | Enzyme activity assays |
| Mass spectrometry | Molecular mass and structure of molybdopterin | Product identification |
| X-ray crystallography | Three-dimensional structure of enzyme | Mechanistic studies |
| Site-directed mutagenesis | Effect of specific amino acid changes on activity | Catalytic residue identification |
| CRISPR knockout | Loss of gene function | Phenotypic analysis |
| CRISPR knock-in | Introduction of specific mutations or tags | Disease modeling |
| Western blot | Protein expression and stability | Subunit analysis |
| Yeast two-hybrid | Protein-protein interactions | Subunit assembly |
Enzymatic Activity Assays
Molybdopterin synthase activity can be measured in vitro using purified enzyme and precursor Z as substrate, followed by detection of molybdopterin by HPLC or mass spectrometry. Alternatively, activity can be assessed indirectly by measuring the conversion of precursor Z to molybdopterin in cell lysates. These assays are essential for characterizing mutant enzymes and for high-throughput screening of inhibitors.
Structural Biology
X-ray crystallography and NMR have been used to determine the structures of molybdopterin synthase from bacteria and eukaryotes, revealing the heterotetrameric architecture and the active site. These studies have identified key residues involved in catalysis and substrate binding. Cryo-EM may be used for larger complexes.
Genetic and Biochemical Studies
Mutational analysis in model organisms such as Escherichia coli and Aspergillus nidulans has been instrumental in defining the roles of MoaE, MoaD, CnxG, and CnxH. Complementation assays with mutant genes can confirm function. Protein-protein interaction studies (e.g., yeast two-hybrid, pull-down) can reveal subunit interactions.
CRISPR-Based Functional Genomics
CRISPR knockout screens can identify genes required for molybdopterin synthase activity and Moco biosynthesis. Point mutations can be introduced to model disease-associated variants. Knock-in of tagged versions allows for localization and interaction studies. Overexpression can test for gain-of-function or rescue.
How CRISPR Can Be Used to Study GO:0030366 molybdopterin synthase activity
Knockout
CRISPR knockout of MOCS2 or MOCS3 in human cell lines (e.g., HEK293T, HeLa) results in loss of molybdopterin synthase activity, accumulation of precursor Z, and reduced Moco-dependent enzyme activities. These models are useful for studying the metabolic consequences of MoCD and for testing rescue strategies. Knockout of MoaE or MoaD in bacteria similarly abolishes activity.
Point Mutation
CRISPR-mediated point mutations can replicate patient-specific missense mutations in MOCS2, such as the conserved cysteine residue in MOCS2A. These models allow assessment of residual activity and stability, and can be used to test pharmacological chaperones. For example, mutation of the catalytic cysteine to serine abolishes activity.
Knock-in
Knock-in of wild-type MOCS2 or tagged versions (e.g., GFP, FLAG) enables visualization of subcellular localization and interaction partners. Knock-in of disease-causing mutations into the endogenous locus provides a more physiologically relevant model than overexpression. This approach can also be used to introduce reporter genes for high-throughput screening.
Overexpression
Overexpression of MOCS2 (both subunits) or MOCS3 in mammalian cells can increase molybdopterin synthase activity and Moco levels, potentially rescuing partial deficiencies. However, overexpression may lead to aggregation or imbalance of subunits, so careful titration is required. Overexpression in bacteria is commonly used for protein purification and structural studies.
How EDITGENE Supports molybdopterin synthase activity Research
Researchers studying molybdopterin synthase activity-related genes often need to determine whether a candidate gene is causally involved in molybdenum cofactor deficiency or related metabolic disorders. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for molybdopterin synthase activity research.
Frequently Asked Questions About molybdopterin synthase activity
What is molybdopterin synthase activity?
Molybdopterin synthase activity (GO:0030366) is the catalytic conversion of precursor Z to molybdopterin, the final step in molybdopterin biosynthesis.
What genes are involved in molybdopterin synthase activity?
Key genes include MOCS2 (encoding both subunits in humans), MOCS3 (sulfurtransferase), and in bacteria MoaE, MoaD, and MoeB.
What diseases are associated with molybdopterin synthase deficiency?
Mutations in MOCS2 or MOCS3 cause molybdenum cofactor deficiency, a severe neurological disorder with neonatal seizures and developmental delay.
How is molybdopterin synthase activity measured?
It is typically measured by incubating purified enzyme with precursor Z and detecting molybdopterin formation by HPLC or mass spectrometry.
What is the structure of molybdopterin synthase?
It is a heterotetramer composed of two small subunits (MoaE/CnxG/MOCS2A) and two large subunits (MoaD/CnxH/MOCS2B).
What is the role of the conserved cysteine in molybdopterin synthase?
The conserved cysteine in the small subunit is essential for catalysis, likely acting as a nucleophile in sulfur transfer.
Can CRISPR be used to study molybdopterin synthase?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect gene function and model disease.
What is precursor Z?
Precursor Z is the substrate of molybdopterin synthase, which is converted to molybdopterin in the final step of Moco biosynthesis.
Is molybdopterin synthase conserved in eukaryotes?
Yes, eukaryotic homologs exist, such as CnxG and CnxH in Aspergillus nidulans and MOCS2A/MOCS2B in humans.
What are potential therapies for molybdenum cofactor deficiency?
Therapies under investigation include dietary molybdenum, precursor Z supplementation, and gene therapy using viral vectors or CRISPR.
Conclusion
Molybdopterin synthase activity (GO:0030366) is a critical enzymatic function in the biosynthesis of the molybdenum cofactor, a cofactor required for essential metabolic enzymes. Its mechanism, structure, and regulation have been elucidated through decades of biochemical and structural studies, revealing a unique sulfur-transfer reaction. Defects in this enzyme cause molybdenum cofactor deficiency, a devastating neurological disorder. Advances in CRISPR-based gene editing now enable precise modeling of the disease and the development of potential therapies. Continued research into molybdopterin synthase will not only deepen our understanding of cofactor biosynthesis but also pave the way for novel treatments.
References
- 1. Adam MP et al.. 1993. Molybdenum Cofactor Deficiency.. PMID: 34870926
- 2. Narrandes NC et al.. 2015. Cleavage of the moaX-encoded fused molybdopterin synthase from Mycobacterium tuberculosis is necessary for activity.. BMC Microbiol 15(1):22 PMID: 25651977
- 3. Rizzi M et al.. 2002. Structural biology of enzymes involved in NAD and molybdenum cofactor biosynthesis.. Curr Opin Struct Biol 12(6):709-20 PMID: 12504674
- 4. Rudolph MJ et al.. 2003. Structural studies of molybdopterin synthase provide insights into its catalytic mechanism.. J Biol Chem 278(16):14514-22 PMID: 12571227
- 5. Wuebbens MM et al.. 2003. Mechanistic and mutational studies of Escherichia coli molybdopterin synthase clarify the final step of molybdopterin biosynthesis.. J Biol Chem 278(16):14523-32 PMID: 12571226
- 6. Tong Y et al.. 2005. Thermodynamic analysis of subunit interactions in Escherichia coli molybdopterin synthase.. Biochemistry 44(7):2595-601 PMID: 15709772
- 7. Wang H et al.. 2019. Structural analysis of molybdopterin synthases from two mycobacterial pathogens.. Biochem Biophys Res Commun 511(1):21-27 PMID: 30765225
- 8. Unkles SE et al.. 1999. Eukaryotic molybdopterin synthase. Biochemical and molecular studies of Aspergillus nidulans cnxG and cnxH mutants.. J Biol Chem 274(27):19286-93 PMID: 10383438
